Tools


Site Haritası

Site Haritası

Akciğer Kanseri

Look closer. See further.

Therapy monitoring and follow-up of lung cancer are key to individualized patient treatment. Monitoring the tumor’s response allows a timely adaptation to the selected therapy. This is important when several therapeutic options are available, as is the case with lung cancer.


After completion of the therapy, a systematic follow-up for the early detection of lung cancer relapse should always be part of the patient’s workup and is described in the corresponding guidelines.

 


Computed Tomography & syngo.via

Computed Tomography & syngo.via - Lung cancer therapy monitoring
CT follow-up examination consisting of baseline and two follow-up scans: evaluation and reporting are supported by syngo.via-based oncology applications
  • through functional examinations like tissue perfusion or iodine quantification SOMATOM CT systems enable an earlier assessment of tumor’s response in the lung or disease progression
  • syngo.via-based1 reading applications permit a standardized and efficient image analysis
  • longitudinal studies of the same patient are automatically registered, the trending of lesion size change is automatically visualized
  • structured reporting allows efficient communication across departments and disciplines

Positron Emission Tomography

Positron Emission Tomography - Lung cancer therapy monitoring
SUV trending in a multi-timepoint PET/CT examination for response monitoring: the effects of the therapy are graphically visualized automatically
  • early predictor of response
  • advanced system calibration of Biograph PET/CT systems helps ensure consistent quantitative accuracy across multiple time points
  • Small, 4 mm LSO crystals provide high sensitivity in detecting local and distant recurrences of lung carcinoma
  • syngo.via with EQ•PET helps reduce technology-induced variations and inter-reader variability by normalizing PET SUV values between different scanners and reconstruction methods
  • Continuous bed motion, made possible by FlowMotion™ technology supports precise disease characterization in therapy monitoring of lung cancer

 


Laboratory diagnostics

  • comprehensive menu of oncology tests, e.g. general and specific tests to assess side-effects in the patient or tumor markers such as carcinoembryonic antigen (CEA)
Bu bilgi yardımcı oldu mu?
Yanıtınız için teşekkür ederiz
Yorumunuzda sayı ve/veya '@' işareti olduğunu fark ettik. Sizinle iletişime geçmemiz için telefon numarası ya da e-posta adresi girmeye çalışıyorsanız lütfen bizimle e-posta formumuz aracılığıyla iletişime geçiniz.

Not: Doğrudan kişisel bir yanıt almak için lütfen bizimle e-posta formumuz üzerinden iletişime geçiniz.

Teşekkür ederiz